These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 16144944)

  • 81. Complement-mediated tumor-specific cell lysis by antibody combinations targeting epidermal growth factor receptor (EGFR) and its variant III (EGFRvIII).
    Klausz K; Berger S; Lammerts van Bueren JJ; Derer S; Lohse S; Dechant M; van de Winkel JG; Peipp M; Parren PW; Valerius T
    Cancer Sci; 2011 Oct; 102(10):1761-8. PubMed ID: 21718386
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Radioimmunodetection of human glioma xenografts by monoclonal antibody to epidermal growth factor receptor.
    Takahashi H; Herlyn D; Atkinson B; Powe J; Rodeck U; Alavi A; Bruce DA; Koprowski H
    Cancer Res; 1987 Jul; 47(14):3847-50. PubMed ID: 3594441
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Cisplatin-induced activation of the EGF receptor.
    Benhar M; Engelberg D; Levitzki A
    Oncogene; 2002 Dec; 21(57):8723-31. PubMed ID: 12483525
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Impact of epidermal growth factor receptor (EGFR) cell surface expression levels on effector mechanisms of EGFR antibodies.
    Derer S; Bauer P; Lohse S; Scheel AH; Berger S; Kellner C; Peipp M; Valerius T
    J Immunol; 2012 Dec; 189(11):5230-9. PubMed ID: 23100515
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Prediction of active drug plasma concentrations achieved in cancer patients by pharmacodynamic biomarkers identified from the geo human colon carcinoma xenograft model.
    Luo FR; Yang Z; Dong H; Camuso A; McGlinchey K; Fager K; Flefleh C; Kan D; Inigo I; Castaneda S; Wong TW; Kramer RA; Wild R; Lee FY
    Clin Cancer Res; 2005 Aug; 11(15):5558-65. PubMed ID: 16061873
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Nimotuzumab enhances temozolomide-induced growth suppression of glioma cells expressing mutant EGFR in vivo.
    Nitta Y; Shimizu S; Shishido-Hara Y; Suzuki K; Shiokawa Y; Nagane M
    Cancer Med; 2016 Mar; 5(3):486-99. PubMed ID: 26778701
    [TBL] [Abstract][Full Text] [Related]  

  • 87. A neutralizing anti-fibroblast growth factor 8 monoclonal antibody shows potent antitumor activity against androgen-dependent mouse mammary tumors in vivo.
    Shimada N; Ishii T; Imada T; Takaba K; Sasaki Y; Maruyama-Takahashi K; Maekawa-Tokuda Y; Kusaka H; Akinaga S; Tanaka A; Shitara K
    Clin Cancer Res; 2005 May; 11(10):3897-904. PubMed ID: 15897591
    [TBL] [Abstract][Full Text] [Related]  

  • 88. EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer.
    Huether A; Höpfner M; Baradari V; Schuppan D; Scherübl H
    Biochem Pharmacol; 2005 Nov; 70(11):1568-78. PubMed ID: 16226226
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Scheduling of paclitaxel and gefitinib to inhibit repopulation for optimal treatment of human cancer cells and xenografts that overexpress the epidermal growth factor receptor.
    Fung AS; Yu M; Ye QJ; Tannock IF
    Cancer Chemother Pharmacol; 2013 Sep; 72(3):585-95. PubMed ID: 23851981
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Global protein profiling reveals anti-EGFR monoclonal antibody 806-modulated proteins in A431 tumor xenografts.
    Lee ST; Ji H; Greening DW; Speirs RW; Rigopoulos A; Pillay V; Murone C; Vitali A; Stühler K; Johns TG; Corner GA; Mariadason JM; Simpson RJ; Scott AM
    Growth Factors; 2013 Oct; 31(5):154-64. PubMed ID: 23957735
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Compartmental distribution of tumor-specific monoclonal antibodies in human melanoma xenografts.
    Lin K; Nagy JA; Xu H; Shockley TR; Yarmush ML; Dvorak HF
    Cancer Res; 1994 Apr; 54(8):2269-77. PubMed ID: 8174137
    [TBL] [Abstract][Full Text] [Related]  

  • 92. The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease.
    Wahl AF; Klussman K; Thompson JD; Chen JH; Francisco LV; Risdon G; Chace DF; Siegall CB; Francisco JA
    Cancer Res; 2002 Jul; 62(13):3736-42. PubMed ID: 12097283
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Cell surface density of p185(c-erbB-2) determines susceptibility to anti-p185(c-erbB-2)-ricin A chain (RTA) immunotoxin therapy alone and in combination with anti-p170(EGFR)-RTA in ovarian cancer cells.
    Dean GS; Pusztai L; Xu FJ; O'Briant K; DeSombre K; Conaway M; Boyer CM; Mendelsohn J; Bast RC
    Clin Cancer Res; 1998 Oct; 4(10):2545-50. PubMed ID: 9796989
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Amphiregulin is a factor for resistance of glioma cells to cannabinoid-induced apoptosis.
    Lorente M; Carracedo A; Torres S; Natali F; Egia A; Hernández-Tiedra S; Salazar M; Blázquez C; Guzmán M; Velasco G
    Glia; 2009 Oct; 57(13):1374-85. PubMed ID: 19229996
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response.
    Sarkaria JN; Carlson BL; Schroeder MA; Grogan P; Brown PD; Giannini C; Ballman KV; Kitange GJ; Guha A; Pandita A; James CD
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2264-71. PubMed ID: 16609043
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Binding of cetuximab to the EGFRvIII deletion mutant and its biological consequences in malignant glioma cells.
    Jutten B; Dubois L; Li Y; Aerts H; Wouters BG; Lambin P; Theys J; Lammering G
    Radiother Oncol; 2009 Sep; 92(3):393-8. PubMed ID: 19616334
    [TBL] [Abstract][Full Text] [Related]  

  • 97. In vitro and in vivo antitumor effect of the anti-CD26 monoclonal antibody 1F7 on human CD30+ anaplastic large cell T-cell lymphoma Karpas 299.
    Ho L; Aytac U; Stephens LC; Ohnuma K; Mills GB; McKee KS; Neumann C; LaPushin R; Cabanillas F; Abbruzzese JL; Morimoto C; Dang NH
    Clin Cancer Res; 2001 Jul; 7(7):2031-40. PubMed ID: 11448921
    [TBL] [Abstract][Full Text] [Related]  

  • 98. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity.
    Hartley JA; Spanswick VJ; Brooks N; Clingen PH; McHugh PJ; Hochhauser D; Pedley RB; Kelland LR; Alley MC; Schultz R; Hollingshead MG; Schweikart KM; Tomaszewski JE; Sausville EA; Gregson SJ; Howard PW; Thurston DE
    Cancer Res; 2004 Sep; 64(18):6693-9. PubMed ID: 15374986
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts.
    Prewett MC; Hooper AT; Bassi R; Ellis LM; Waksal HW; Hicklin DJ
    Clin Cancer Res; 2002 May; 8(5):994-1003. PubMed ID: 12006511
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Development and evaluation of a cetuximab-based imaging probe to target EGFR and EGFRvIII.
    Aerts HJ; Dubois L; Hackeng TM; Straathof R; Chiu RK; Lieuwes NG; Jutten B; Weppler SA; Lammering G; Wouters BG; Lambin P
    Radiother Oncol; 2007 Jun; 83(3):326-32. PubMed ID: 17531336
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.